Few medical questions carry as much fear and as much outdated information as this one. For two decades women were told hormone therapy was dangerous, full stop. The honest answer is more specific and more useful: it depends on who you are, when you start, and which type — and each of those three has a knowable answer.

Where we stand: Menova is an independent publication. We sell no hormones and have no product to push, so we have no reason to talk you into or out of anything. We are not your doctor, and this is general education, not medical advice or a recommendation.

Where the fear came from

Most of it traces to early results from the Women's Health Initiative, released in 2002, reporting increased risks of breast cancer, heart disease, and stroke. Millions of women stopped hormone therapy within months.

What got lost in the headlines:

  • The participants were older. Average age at enrolment was 63, well past the typical age of starting hormone therapy for symptoms. Many were more than a decade past menopause
  • One specific regimen was studied — oral conjugated equine estrogen, with or without a specific synthetic progestin. Transdermal estradiol and micronized progesterone, which are what most women use now, were not what was tested
  • The two arms told different stories. In the estrogen-only arm — women who had had a hysterectomy — breast cancer risk was not increased and was, if anything, slightly lower
  • Later analysis by age found the risk-benefit balance differs substantially for women who start near menopause. This is now often called the timing hypothesis

None of that makes the risks imaginary. It means the headline was applied to a group it did not describe.

Where the guidance stands now

Major bodies including The Menopause Society take an individualized position: for healthy women under 60, or within about ten years of their last period, with bothersome symptoms, the benefits of hormone therapy generally outweigh the risks. The balance shifts for women starting substantially later, and for those with particular medical histories.

So hormone therapy is not uniformly safe or unsafe. It is a calculation, and the inputs are knowable.

The risks, in absolute terms

Percentages sound alarming and tell you nothing without a baseline. Here is what the numbers actually look like.

Breast cancer. Estrogen-only therapy has not been shown to increase risk in the main trial evidence. Combined estrogen-plus-progestogen therapy carries a small increase, typically described by menopause societies as fewer than one additional case per 1,000 women per year of use, growing with duration and declining after stopping. Set against that: alcohol, physical inactivity, and excess weight after menopause carry risks of comparable or larger magnitude, and none comes with a warning conversation. Our full treatment is in HRT and breast cancer risk in real numbers.

Blood clots. This is the one where your choice genuinely changes the risk. Oral estrogen carries a small increase in venous thromboembolism, concentrated in the first year and in women with existing risk factors. Transdermal estrogen — patch, gel, or spray — has not been shown to carry the same increase, because it bypasses first-pass liver metabolism. That single decision is the most actionable risk information in menopause care; see HRT and blood clots.

Stroke. A small increase has been associated with oral estrogen, again with transdermal appearing more favourable, and with age at initiation mattering.

Endometrial cancer. Only a risk if you take estrogen without adequate progestogen protection and still have a uterus — which is precisely why the progestogen is prescribed. See progesterone in menopause.

Gallbladder disease, more associated with oral than transdermal.

The benefits, stated as plainly

A risk conversation that only counts risks is not a decision aid.

  • Vasomotor symptoms. Hormone therapy is the most effective treatment available for hot flashes and night sweats, with improvement often within four to six weeks
  • Vaginal and urinary symptoms, which otherwise worsen over time rather than settling; local vaginal estrogen is a separate and even lower-risk decision, see is vaginal estrogen safe
  • Bone. It reduces bone loss and fracture risk — an established benefit, though the protection stops when the treatment stops; see bone health in menopause
  • Sleep, indirectly but substantially, when night sweats are what is waking you
  • Quality of life, which is not a soft consideration when someone has not slept properly in two years

For women with early or premature menopause, the calculation is different again: guidance generally recommends hormone therapy until around the average age of natural menopause, because the comparison is not "risk versus no risk" but versus the consequences of years without estrogen; see early and surgical menopause.

When it is generally not used

Hormone therapy is usually avoided with a history of breast cancer or other hormone-sensitive cancer, unexplained vaginal bleeding that has not been investigated, previous venous thromboembolism or stroke, or active liver disease. Some of these are absolute and some warrant specialist input rather than a flat no — a history of clots, for instance, often leads to the transdermal route rather than to refusal.

If hormone therapy is genuinely not an option, effective alternatives exist and should be offered; see non-hormonal prescription options and managing menopause after breast cancer.

What changed in 2025

In late 2025 the FDA announced removal of the long-standing boxed warning from many menopausal hormone therapy products, reflecting long-running arguments that the class labelling — derived largely from systemic therapy studies — overstated risk, particularly for low-dose vaginal products.

What that changed: how risk is framed on the box. What it did not change: the underlying evidence. "The warning was removed" is not the same as "there is no risk." See what the 2025 FDA change actually meant.

What actually changes your personal number

  • Your age and years since menopause — the single biggest modifier
  • Whether you have a uterus, which decides whether you need a progestogen at all
  • The route — transdermal versus oral, which changes clot risk
  • The type of progestogen, where micronized progesterone may compare more favourably than older synthetic progestins on limited observational evidence
  • Duration, since the breast cancer association grows with years of combined use
  • Your own history: clots, cancer, migraine with aura, cardiovascular disease, liver disease, family history

How to have the conversation

Ask for your numbers, not the population's:

"Given my age, my history, and the fact that I still have a uterus — what's my baseline risk, and how much would this specific regimen change it in absolute terms? And how does that compare with the risks of not treating my symptoms?"

Also worth asking: which route you would be started on and why, when you would reassess, and what the plan is if the first regimen does not suit you — because the first plan is rarely the final plan; see your first three months on HRT, HRT types and forms, and how long you can stay on HRT.

The honest summary

For most healthy women under 60 or within ten years of menopause, hormone therapy is an effective treatment whose risks are small in absolute terms and partly modifiable by the route you choose. Those risks are real and should be disclosed. Anyone telling you it is definitely safe, or definitely dangerous, is offering a simpler story than the evidence supports.

Walking in organized changes this conversation more than anything else you can do. The free 2-minute Menova self-check turns your symptoms into a printable summary, and the free visit prep sheet has space for the history that determines the answer. No account, not a diagnosis, and your answers never leave your device.

Three things written since, which this page assumes but does not cover: what the WHI actually found — where the fear came from and what it did and did not show; when you can't decide, for the point where you know the numbers and still cannot weigh them; and resolving conflicting advice, for when two confident sources say opposite things.

This article is general education, not medical advice, and not a recommendation for or against hormone therapy. Risk estimates are population averages and cannot be applied directly to an individual. Decide with a licensed clinician who knows your full history.

Sources: The Menopause Society — Hormone Therapy, ACOG — Hormone Therapy, NICE NG23 — Menopause, and FDA — Menopause.